Celsion Corporation (NASDAQ: CLSN), an oncology drug development
company, today announced financial results for the three and six
months ended June 30, 2020, and provided an update on clinical
development programs with GEN-1, its DNA-mediated IL-12
immunotherapy currently in Phase II development for the treatment
of advanced stage ovarian cancer, and ThermoDox®, its proprietary
heat-activated liposomal encapsulation of doxorubicin currently in
Phase III development for the treatment of hepatocellular
carcinoma, or primary liver cancer.
“GEN-1, our oncology-focused immunotherapy,
continues to show encouraging results at the 100 mg/m² dose cohort
in the OVATION 2 Study, which is consistent with the results
reported from our earlier Phase Ib trial (the OVATION 1 Study) in
advanced-stage ovarian cancer. In June 2020, the Data Safety
Monitoring Board (DSMB) for the OVATION 2 Study recommended that
the Phase II portion of the OVATION Study proceed with the dose of
100 mg/m2,” reported Michael H. Tardugno, Celsion’s chairman,
president and chief executive officer. “These findings were
reinforced by strong progression-free survival (PFS) when comparing
study patients to a statistically validated synthetic control arm
(SCA) of matched patients from prior studies. In July 2020, we
announced the randomization of the first two patients in the Phase
II OVATION 2 Study. This milestone was achieved approximately five
months ahead of our previously announced schedule. We have a very
aggressive recruitment program and anticipate completing enrollment
of 105 patients in the second quarter of 2021. Importantly, as an
open-label study, clinical updates will be provided throughout the
course of treatment including response rates and surgical resection
scores,” Mr. Tardugno added.
Continuing his comments, Mr. Tardugno noted, “In
early July, Celsion received a wholly unexpected recommendation
from the independent Data Monitoring Committee (DMC) to consider
stopping the global Phase III OPTIMA Study. This recommendation was
made following the DMC’s second pre-planned interim safety and
efficacy analysis of the OPTIMA Study on July 9, 2020. The DMC’s
analysis found that the pre-specified boundary for stopping the
trial for futility of 0.900 was crossed with an actual value of
0.903. However, the p-value of 0.524 for this analysis provides a
high level of uncertainty as to the actual hazard ratio value,
therefore, the DMC left the final decision of whether to stop the
OPTIMA Study to the Company.
Mr. Tardugno further stated, “This development
had never been anticipated by the Company or our advisors, nor
would it have been forecasted by the first pre-planned efficacy
analysis. Further, blinded data available to the Company appeared
to be tracking well against the sub-group analysis of the Company’s
earlier HEAT Study, upon which the OPTIMA Study is based.”
In early August, after conducting additional
analyses of the unblinded data from the second pre-planned interim
analysis, the Company announced plans to continue following
patients for overall survival (OS), noting that the unexpected and
marginally crossed futility boundary, suggested by the Kaplan-Meier
analysis at the second interim analysis, may be associated with a
data maturity issue. Additionally, Celsion reported that it is
sending all clinical trial data, including Chemistry, Manufacturing
and Controls (CMC) data, to the National Institutes of Health (NIH)
for independent analysis, including computed tomography (CT) scans
for NIH’s evaluation of PFS. Depending on the trends noted during
the OS follow-up period, Celsion may choose to discontinue the
Study at any time. The Company also notes that the vast majority of
expenses related to the OPTIMA Study already have been
incurred.
Recent Developments
GEN-1 Immunotherapy
Initiation of Phase II OVATION 2 Study
in Advanced Ovarian Cancer. In July 2020, the Company
announced the randomization of the first two patients in the Phase
II portion of the OVATION 2 Study with GEN-1 in advanced ovarian
cancer. The Company anticipates completing enrollment of up to 118
patients in the second quarter of 2021. Because this is an
open-label study, clinical updates will be provided throughout the
course of treatment including response rates and surgical resection
scores.
The OVATION 2 Study combines GEN-1 with
standard-of-care neoadjuvant chemotherapy (NACT) in patients newly
diagnosed with Stage III/IV ovarian cancer. NACT is designed to
shrink the cancer as much as possible for optimal surgical removal
after three cycles of chemotherapy. Following NACT, patients
undergo interval debulking surgery, followed by three adjuvant
cycles of chemotherapy and up to nine additional weekly GEN-1
treatments, the goal of which is to delay progression and improve
OS. The OVATION 2 Study is an open-label, 1-to-1 randomized trial,
80% powered to show the equivalent of a 33% improvement in PFS
(HR=0.75), the primary endpoint, when comparing the treatment arm
(standard of care + GEN-1) with the control arm (standard of care
alone).
DSMB Recommends GEN-1 to Proceed to
Phase II of the OVATION 2 Study in Advanced Ovarian
Cancer. In May 2020, the Company announced the final
recommendations of the DSMB following completion of the Phase I
dose-finding and tolerance portion of the OVATION 2 Study with
GEN-1 in advanced (Stage III/IV) ovarian cancer. Based on favorable
safety data from 15 randomized patients, the DSMB recommended that
the Phase II portion of the OVATION Study proceed with the dose of
100 mg/m2. The DSMB also determined that safety is satisfactory
with an acceptable risk/benefit, and that patients tolerate up to
17 doses of GEN-1 during a course of treatment that lasts up to six
months. No dose limiting toxicities were reported.
In March 2020, the Company announced the
following clinical development achievements for GEN-1:
● |
Highly encouraging initial clinical data from the first 15 patients
enrolled in the ongoing Phase I/II OVATION 2 Study for patients
newly diagnosed with Stage III and IV ovarian cancer. GEN-1 plus
standard NACT produced positive dose-dependent efficacy results,
with no dose-limiting toxicities, which correlates well with
successful surgical outcomes as summarized below: |
|
o |
Of the 15 patients treated in the Phase I portion of the OVATION 2
Study, nine were treated with GEN-1 at a dose of 100 mg/m² plus
NACT and six were treated with NACT only. All 15 had successful
resections of their tumors, with seven out of nine patients (78%)
in the GEN-1 treatment arm having an R0 resection, which indicates
a microscopically margin-negative resection in which no gross or
microscopic tumor remains in the tumor bed. Only three out of six
patients (50%) in the NACT only treatment arm had an R0
resection |
|
o |
When combining these results with the surgical resection rates
observed in the Company’s prior Phase Ib dose-escalation trial (the
OVATION 1 Study), a population of patients with inclusion criteria
identical to the OVATION 2 Study, the data reflect the strong
dose-dependent efficacy of adding GEN-1 to the current standard of
care NACT: |
|
|
|
|
% of Patients with |
|
|
|
|
|
R0 Resections |
|
|
|
|
|
|
|
0, 36, 47 mg/m² of GEN-1 plus
NACT |
|
n=12 |
|
|
42 |
% |
61, 79, 100 mg/m² of GEN-1
plus NACT |
|
n=17 |
|
|
82 |
% |
● |
Medidata-matched patient data from a SCA compared with results from
the Phase Ib dose-escalating OVATION 1 Study with GEN-1 in Stage
III/IV ovarian cancer patients showed positive results in PFS. The
HR was 0.53 in the intent-to-treat group, showing strong signals of
efficacy. Medidata is a globally recognized leader in clinical data
management. GEN-1’s strong and encouraging treatment effect,
evidenced by the SCA, suggests a potentially remarkable improvement
in PFS, an FDA-recognized surrogate for OS, and appears to confirm
the science behind IL-12’s ability to recruit the innate and
adaptive elements of the immune system to fight malignancies. The
strong PFS trend is supported by previously published translational
data that clearly demonstrate the pro-immune changes in the tumor
microenvironment associated with loco-regional GEN-1 therapy. PFS
data generated from this analysis comparing GEN-1 with SCA showed
the following: |
GEN-1 Population |
|
PFS Hazard Ratio (Confidence Interval) |
Intent-to-treat, n=15 |
|
0.53 (95% CI 0.16, 1.73); log-rank p = 0.29 |
Per-protocol, n=14 |
|
0.33 (95% CI 0.08, 1.37); log-rank p = 0.11 |
● |
The European Medicines Agency (EMA) Committee for Orphan Medicinal
Products recommended that GEN-1 be designated as an orphan
medicinal product for the treatment of ovarian cancer. As
established by the EMA, this designation provides for scientific
advice and certain regulatory assistance during the product
development phase, direct access to centralized marketing
authorization and certain financial incentives for companies
developing new therapies intended for the treatment of a
life-threatening or chronically debilitating condition that affects
no more than five in 10,000 people in the European Union. GEN-1
previously received orphan drug designation from the FDA. |
ThermoDox®
Patients in Phase III OPTIMA Study Will
Continue to be Followed for Overall Survival. In August
2020, the Company provided an update on its ongoing review of
unblinded data from the second pre-planned interim analysis of the
global Phase III OPTIMA Study. The Company announced it will
continue following patients for OS, noting that the unexpected and
marginally crossed futility boundary suggested by the Kaplan-Meier
analysis at the second interim analysis on July 9, 2020 may be
associated with a data maturity issue. The Company further notes
that 26 consecutive patient deaths represented exclusively in the
second analysis behave far differently from the balance of the
patients who have died as of that date. Removing the 26 consecutive
patient deaths, which occurred between September 2019 and March
2020, from the pre-planned interim analysis suggests that the
OPTIMA Study OS pattern is similar to the prospective HEAT Study
subgroup upon which the OPTIMA Study is based, at the approximate
comparable point in time. In addition, subsequent to the second
interim analysis there were eight patient deaths in a 3:1 ratio of
control arm to treatment arm patients, which further supports a
concern for data maturity.
It was further noted that OPTIMA Study sites in
China and Vietnam, which enrolled over 37% of the subjects, joined
the Study approximately 12 and 18 months, respectively, after the
trial was initiated. The Kaplan-Meier curves for both geographies
demonstrate a potential data maturity issue when compared with the
behavior of the HEAT Study subgroup and other OPTIMA Study testing
site regions. The China sites, in particular, show a negative
Kaplan-Meier curve, yet with a 56% improvement in the treatment arm
in the median time to death. The Vietnam sites show a marginal
Kaplan-Meier benefit, yet with a 45% improvement in the treatment
arm in the median time to death. The Company believes that this
dichotomy must be reconciled, most probably with longer follow up,
before it can determine the Study’s direction.
Recommendation from the Independent DMC
to Consider Stopping the Phase III OPTIMA Study of ThermoDox® in
Primary Liver Cancer. In July 2020, the Company announced
that it received a recommendation from the independent DMC to
consider stopping the global Phase III OPTIMA Study. The
recommendation was made following the second pre-planned interim
safety and efficacy analysis by the DMC on July 9, 2020. The DMC
analysis found that the pre-specified boundary for stopping the
trial for futility of 0.900 was crossed with an actual value of
0.903. However, the p-value of 0.524 for this analysis provides
uncertainty; subsequently, the DMC left the final decision of
whether or not to stop the OPTIMA Study to Celsion. There were no
safety concerns noted during the interim analysis.
The statistical plan for the OPTIMA Study
included two interim efficacy analyses by the DMC. The first
interim analysis was announced in November 2019 following data lock
in August 2019 after the prescribed minimum number of 128 patient
events (deaths) was reached, and the second interim analysis was
conducted on July 9, 2020 following data lock in April 2020 after
the prescribed minimum number of 158 events was reached.
Corporate Developments
Strengthened Balance Sheet Through a $10
Million Underwritten Offering of Common Stock. In June
2020, the Company entered into an underwriting agreement relating
to the sale of 2,666,667 shares of its common stock at an offering
price of $3.75 per share. The net proceeds from the offering were
$9.3 million, after deducting underwriting discounts and
commissions, but before expenses payable by the Company. The shares
of common stock were sold to both existing and new institutional
investors of the Company. Oppenheimer & Co. Inc. acted as the
sole underwriter for the offering.
Received $1.8 Million in Non-Dilutive
Funding from the Sale of New Jersey State Net Operating
Losses. In April 2020, the Company announced it received
$1.8 million of net cash proceeds from the sale of approximately
$1.9 million of its unused New Jersey net operating losses (NOLs).
The NOL sales cover the tax years 2017 and 2018 and are
administered through the New Jersey Economic Development
Authority’s (NJEDA) Technology Business Tax Certificate Transfer
(NOL) Program. An additional sale of $2.0 million of unused New
Jersey NOLs anticipated in the second half of 2020 will further
increase Celsion’s cash reserves on a non-dilutive basis.
Second Quarter Financial
Results
For the quarter ended June 30, 2020, Celsion
reported a net loss of $5.3 million ($0.18 per share), compared
with $5.9 million ($0.29 per share) in the same period of 2019.
Operating expenses were $4.9 million in the second quarter of 2020,
which represented a $0.8 million (14%) decrease from $5.7 million
in the same period of 2019.
The Company ended the second quarter of 2020
with $25.5 million in cash, investment securities and accrued
interest receivable. With $25.5 million in cash as of June 30, 2020
coupled with future sales of the Company’s New Jersey NOL’s, the
Company believes it has sufficient capital resources to fund its
operations into the fourth quarter of 2021.
Research and development expenses decreased $0.6
million to $3.0 million in the second quarter of 2020, compared
with $3.6 million in the second quarter of 2019. Clinical
development costs for the Phase III OPTIMA Study decreased $0.6
million to $0.6 million in the second quarter of 2020, compared
with $1.2 million in the second quarter of 2019, due to the
completion of enrollment in this 556-patient trial in August 2018.
Costs associated with the OVATION 2 Study increased to $0.2 million
in the second quarter of 2020 compared with $0.1 million in the
same period of 2019. Other costs related to clinical supplies and
regulatory support for the ThermoDox® and GEN-1 clinical
development programs increased to $2.3 million in the current
quarter from $2.2 million in the second quarter of 2019 largely
driven by higher manufacturing costs for GEN-1 clinical supplies
for the Phase II portion of the OVATION 2 Study.
General and administrative expenses were $1.9
million in the second quarter of 2020, compared with $2.1 million
in the same period of 2019. The 11% decrease was primarily
attributable to lower professional fees incurred during the second
quarter of 2020.
In connection with the Company’s venture debt
facility with Horizon entered in late June 2018, the Company
incurred interest expense of $0.3 million during the second quarter
of 2020. This compares with interest expense of $0.4 million in the
comparable prior-year period.
Six Month Financial Results
For the six months ended June 30, 2020, the
Company reported a net loss of $10.4 million ($0.37 per share),
compared with $8.3 million ($0.42 per share) in the same period of
2019. Operating expenses were $9.8 million during the first six
months of 2020, which represented a $0.9 million (8%) decrease from
$10.7 million in the same period of 2019.
Net cash used for operating activities was $7.9
million in the first six months of 2020, compared with $10.2
million in the same period in 2019. This was in line with the
Company’s projected cash utilization for 2020 of approximately $15
million, or an average of approximately $3.75 million per quarter.
Cash provided by financing activities was $18.6 million during the
first six months of 2020 resulting from equity offerings in March
2020 and June 2020, and proceeds from the exercise of stock
options.
Research and development expenses decreased $0.3
million to $6.0 million in the first half of 2020 from $6.3 million
in the first half of 2019. Clinical development costs for the Phase
III OPTIMA Study decreased by $0.8 million to 1.3 million in the
first half of 2020, compared with $2.1 million in the first half of
2019, due to the completion of enrollment in this 556-patient trial
in August 2018. Costs associated with the OVATION 2 Study increased
to $0.5 million in the first half of 2020, compared with $0.2
million in the comparable six-month period in 2019. Other costs
related to clinical supplies and regulatory support for the
ThermoDox® and GEN-1 clinical development programs increased by
$0.4 million in the first half of 2020, compared with the same
prior-year period due to higher manufacturing costs for GEN-1
clinical supplies for the Phase II portion of the OVATION 2
Study.
Other expenses during the first half of 2020
included a non-cash charge of $0.3 million for the change in
valuation of the earn-out milestone liability for the GEN-1 ovarian
product candidate, compared with a non-cash gain of $2.7 million,
net of charge of $0.4 million for the 200,000 warrant issuance
related to an amendment for the potential milestone payments for
the GEN-1 ovarian product candidate during the comparable
prior-year period. The Company realized $0.1 million of interest
income during the first half of 2020 and $0.3 million in the
comparable prior-year period. In connection with the Company’s
venture debt facility with Horizon entered in late June 2018, the
Company incurred interest expense of $0.7 million during the first
six months of 2020 and
2019. Second Quarter Conference
Call
The Company will host a conference call to
provide a business update and discuss its second quarter 2020
financial results at 11:00 a.m. EDT today. To participate in the
call, interested parties may dial 1-800-353-6461 (Toll-Free/North
America) or 1-334-323-0501 (International/Toll) 10 minutes before
the call is scheduled to begin, and ask for the Celsion Corporation
Second Quarter 2020 Earnings Call (Conference Code: 4777957). The
call will also be broadcast live on the internet at
www.celsion.com. The call will be archived for replay through
August 28, 2020. The replay can be accessed at 1-719-457-0820 or
1-888-203-1112 using Conference ID: 4777957. An audio replay of the
call will also be available on the Company’s website,
www.celsion.com, for 90 days after 2:00 p.m. EDT Friday, August 14,
2020.
About Celsion Corporation
Celsion is a fully integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including immunotherapies, DNA-based therapies and directed
chemotherapies. The Company’s product pipeline includes GEN-1, a
DNA-based immunotherapy for the localized treatment of ovarian
cancer and ThermoDox®, a proprietary heat-activated liposomal
encapsulation of doxorubicin, currently in Phase III development
for the treatment of primary liver cancer and in development for
other cancer indications. Celsion has two feasibility stage
platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit: http://www.celsion.com.
(CLSN-FIN).
Celsion wishes to inform readers that
forward-looking statements in this release are made pursuant to the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data; the
significant expense, time, and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future
development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in Celsion’s periodic reports and
prospectuses filed with the Securities and Exchange Commission.
Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Celsion Investor ContactJeffrey
W. Church609-482-2455 jchurch@celsion.com
LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.com
[Tables to Follow]
Celsion
CorporationCondensed Statements of
Operations(in thousands except per share
amounts)
|
|
Three Months EndedJune 30, |
|
|
Six Months EndedJune 30, |
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing revenue |
|
$ |
125 |
|
|
$ |
125 |
|
|
$ |
250 |
|
|
$ |
250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
2,991 |
|
|
|
3,558 |
|
|
|
6,043 |
|
|
|
6,326 |
|
General and administrative |
|
|
1,901 |
|
|
|
2,137 |
|
|
|
3,740 |
|
|
|
4,354 |
|
Total operating expenses |
|
|
4,892 |
|
|
|
5,695 |
|
|
|
9,783 |
|
|
|
10,680 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
operations |
|
|
(4,767 |
) |
|
|
(5,570 |
) |
|
|
(9,533 |
) |
|
|
(10,430 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
(expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) gain from change in valuation of earn-out milestone
liability |
|
|
(256 |
) |
|
|
(127 |
) |
|
|
(298 |
) |
|
|
2,600 |
|
Fair value of warrants issued in connection with amendment to
modify GEN-1 earn-out milestone payment |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(400 |
) |
Interest expense, investment income and other income (expense),
net |
|
|
(320 |
) |
|
|
(208 |
) |
|
|
(569 |
) |
|
|
(442 |
) |
Total other income (expense), net |
|
|
(576 |
) |
|
|
(335 |
) |
|
|
(867 |
) |
|
|
2,158 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(5,343 |
) |
|
$ |
(5,904 |
) |
|
$ |
(10,400 |
) |
|
$ |
(8,272 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common
share Basic and diluted |
|
$ |
(0.18 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.37 |
) |
|
$ |
(0.42 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
shares outstanding Basic and diluted |
|
|
29,887 |
|
|
|
20,606 |
|
|
|
27,831 |
|
|
|
19,713 |
|
Celsion
CorporationSelected Balance Sheet
Information(in thousands)
|
|
June 30, 2020(Unaudited) |
|
|
December 31,2019 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
22,654 |
|
|
$ |
6,875 |
|
Investment securities and interest receivable on investment
securities |
|
|
2,799 |
|
|
|
8,007 |
|
Advances, deposits on clinical programs and other current
assets |
|
|
1,343 |
|
|
|
1,353 |
|
Total current assets |
|
|
26,796 |
|
|
|
16,235 |
|
|
|
|
|
|
|
|
|
|
Property and equipment |
|
|
339 |
|
|
|
405 |
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
Deferred tax asset |
|
|
-– |
|
|
|
1,820 |
|
In-process research and development |
|
|
15,736 |
|
|
|
15,736 |
|
Goodwill |
|
|
1,976 |
|
|
|
1,976 |
|
Operating lease right-of-use assets, net |
|
|
1,245 |
|
|
|
1,432 |
|
Other intangible assets, deposits and other assets |
|
|
631 |
|
|
|
674 |
|
Total other assets |
|
|
19,588 |
|
|
|
21,638 |
|
Total assets |
|
$ |
46,723 |
|
|
$ |
38,278 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’
EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
$ |
3,910 |
|
|
$ |
5,166 |
|
Notes payable – current portion |
|
|
4,386 |
|
|
|
1,840 |
|
Operating lease liability – current portion |
|
|
410 |
|
|
|
388 |
|
Deferred revenue - current portion |
|
|
500 |
|
|
|
500 |
|
Total current liabilities |
|
|
9,206 |
|
|
|
7,894 |
|
|
|
|
|
|
|
|
|
|
Earn-out milestone liability |
|
|
6,015 |
|
|
|
5,718 |
|
Notes payable |
|
|
5,611 |
|
|
|
7,963 |
|
Operating lease liability |
|
|
933 |
|
|
|
1,144 |
|
Deferred revenue and other liabilities |
|
|
750 |
|
|
|
1,000 |
|
Total liabilities |
|
|
22,515 |
|
|
|
23,719 |
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
Common stock |
|
|
332 |
|
|
|
232 |
|
Additional paid-in capital |
|
|
324,870 |
|
|
|
304,886 |
|
Accumulated other comprehensive gain (loss) |
|
|
8 |
|
|
|
43 |
|
Accumulated deficit |
|
|
(300,917 |
) |
|
|
(290,517 |
) |
|
|
|
24,293 |
|
|
|
14,644 |
|
Less: Treasury stock |
|
|
(85 |
) |
|
|
(85 |
) |
Total stockholders’ equity |
|
|
24,208 |
|
|
|
14,559 |
|
Total liabilities and stockholders’ equity |
|
$ |
46,723 |
|
|
$ |
38,278 |
|
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024